Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

Leuk Res. 2013 Aug;37(8):872-6. doi: 10.1016/j.leukres.2013.05.006. Epub 2013 Jun 4.

Abstract

Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Cytogenetic Analysis
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Resistance, Neoplasm / drug effects*
  • Etoposide / administration & dosage
  • Female
  • Follow-Up Studies
  • Genotype
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / pathology
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Recurrence
  • Remission Induction
  • Risk Factors
  • Salvage Therapy / methods
  • Survival Analysis

Substances

  • Etoposide
  • Cyclophosphamide